This list documents the scholarly sources, textbooks, and reference works on which the book The GABA Fix is based, either directly or indirectly. The list is updated on an ongoing basis.
This list documents the scientific sources, textbooks, and reference works cited in *The GABA Fix: A Doctor’s Guide to Better Sleep, Less Anxiety, and a Calmer Mind* by Bernd Guzek, MD, PhD. The list is updated periodically.
GABA: Relaxation for Body and Mind
McEwen, B.S. (2007): Physiology and Neurobiology of Stress and Adaptation — Central Role of the Brain
A landmark review on how the brain orchestrates the stress response. McEwen describes the concept of “allostatic load” — the cumulative wear and tear from chronic stress — and how it damages the very brain circuits that regulate calm and recovery, including GABAergic systems.
Source: Physiological Reviews, 87(3), 873–904. doi.org/10.1152/physrev.00041.2006
Schneiderman, N., Ironson, G. & Siegel, S.D. (2005): Stress and Health — Psychological, Behavioral, and Biological Determinants
Comprehensive overview of how stress affects health across psychological, behavioral, and biological dimensions. Covers the pathways from chronic stress to cardiovascular disease, immune dysfunction, and mental health disorders.
Source: Annual Review of Clinical Psychology, 1, 607–628. doi.org/10.1146/annurev.clinpsy.1.102803.144141
What Are Neurotransmitters?
Bear, M.F., Connors, B.W. & Paradiso, M.A. (2020): Neuroscience — Exploring the Brain (4th ed.)
One of the most widely used neuroscience textbooks. Provides the foundational explanation of how neurotransmitters work — from synaptic transmission and receptor binding to the balance between excitation and inhibition that underlies all brain function.
Source: Lippincott Williams & Wilkins, Philadelphia.
Kandel, E.R. et al. (2013): Principles of Neural Science (5th ed.)
The definitive reference in neuroscience, co-authored by Nobel laureate Eric Kandel. Covers everything from the molecular biology of ion channels to the neuroscience of emotion and behavior, including detailed chapters on GABA and glutamate signaling.
Source: McGraw-Hill, New York.
What Does GABA Do in the Body?
Möhler, H. (2006): GABA(A) Receptor Diversity and Pharmacology
Detailed review of the different subtypes of GABA-A receptors and their pharmacological profiles. Explains why drugs targeting specific GABA-A subtypes can produce calming effects without sedation — the key principle behind modern anxiolytic development.
Source: Cell and Tissue Research, 326(2), 505–516. doi.org/10.1007/s00441-006-0270-8
Petroff, O.A.C. (2002): GABA and Glutamate in the Human Brain
Foundational paper on the distribution and metabolism of GABA and glutamate in the living human brain, measured using magnetic resonance spectroscopy. Demonstrates the tight coupling between these two neurotransmitters and the consequences when their balance shifts.
Source: The Neuroscientist, 8(6), 562–573. doi.org/10.1177/1073858402238515
Sieghart, W. (1995): Structure and Pharmacology of GABA-A Receptor Subtypes
Comprehensive early review of GABA-A receptor subunit composition and how different subunit combinations create distinct receptor subtypes with different pharmacological properties. Foundational reference for understanding why different GABA-targeting drugs have different effects.
Source: Pharmacological Reviews, 47(2), 181–234.
GABA’s Counterpart: Glutamate
Coyle, J.T. & Puttfarcken, P. (1993): Oxidative Stress, Glutamate, and Neurodegenerative Disorders
Describes how excess glutamate triggers excitotoxicity — a process in which overactivated neurons are essentially stimulated to death. Links this mechanism to Alzheimer’s, Parkinson’s, and ALS, establishing the critical importance of the GABA-glutamate balance.
Source: Science, 262(5134), 689–695. doi.org/10.1126/science.7901908
Meldrum, B.S. (2000): Glutamate as a Neurotransmitter in the Brain — Review of Physiology and Pathology
Authoritative review of glutamate’s dual role as the brain’s primary excitatory messenger and, when dysregulated, a driver of neurological damage. Covers the NMDA, AMPA, and kainate receptor systems and their clinical relevance.
Source: Journal of Nutrition, 130(4S Suppl), 1007S–1015S. doi.org/10.1093/jn/130.4.1007S
Stress Is a GABA Killer
Bremner, J.D. et al. (1997): Stress-Induced Changes in GABA Receptors in PTSD
Early evidence that chronic stress — particularly traumatic stress — directly alters GABA receptor function. Found measurable changes in the GABA system of PTSD patients, linking stress exposure to reduced inhibitory capacity in the brain.
Source: Annals of the New York Academy of Sciences, 821, 265–279. doi.org/10.1111/j.1749-6632.1997.tb48285.x
Goddard, A.W. et al. (2001): The Role of GABA in Anxiety Disorders
Reviews the evidence linking GABA dysfunction to anxiety disorders. Demonstrates that patients with panic disorder and generalized anxiety show measurably reduced GABA levels in specific brain regions, supporting the GABA-deficit model of anxiety.
Source: Depression and Anxiety, 13(3), 95–104. pubmed.ncbi.nlm.nih.gov/12662130
Jie, F. et al. (2018): Stress in Regulation of GABA Amygdala System and Relevance to Neuropsychiatric Diseases
Examines how stress specifically disrupts GABAergic signaling in the amygdala — the brain’s fear center. Explains the molecular mechanisms by which chronic stress weakens GABA’s ability to contain anxiety and fear responses.
Source: Frontiers in Neuroscience, 12, 562. doi.org/10.3389/fnins.2018.00562
Skilbeck, K.J., Hensley, M.J. & Rees, S.M. (2010): The Effect of Stress on GABAergic Neurotransmission in the Brain
Systematic review of how different types of stress — acute, chronic, prenatal — affect GABA transmission throughout the brain. Demonstrates that chronic stress consistently downregulates GABA function, creating a vicious cycle of increasing vulnerability.
Source: Behavioural Brain Research, 223(1), 37–52. doi.org/10.1016/j.bbr.2011.04.055
The Gut as a GABA Factory
Barrett, E. et al. (2012): γ-Aminobutyric Acid Production by Culturable Bacteria from the Human Intestine
Demonstrated that specific gut bacteria — particularly Lactobacillus and Bifidobacterium strains — can produce GABA directly in the intestine. A key study establishing the gut as an independent source of this neurotransmitter.
Source: Journal of Applied Microbiology, 113(2), 411–417. doi.org/10.1111/j.1365-2672.2012.05344.x
Berdoy, M., Webster, J.P. & Macdonald, D.W. (2000): Fatal Attraction in Rats Infected with Toxoplasma gondii
A striking demonstration of how microorganisms can manipulate host behavior through neurotransmitter systems. Toxoplasma-infected rats lose their fear of cats — mediated in part through altered GABA and dopamine signaling. Illustrates the power of the gut-brain axis.
Source: Proceedings of the Royal Society B, 267(1452), 1591–1594. doi.org/10.1098/rspb.2000.1182
Cryan, J.F. & Dinan, T.G. (2012): Mind-Altering Microorganisms — The Impact of the Gut Microbiota on Brain and Behaviour
Highly influential review establishing the concept of the microbiota-gut-brain axis. Summarizes evidence that gut bacteria influence mood, anxiety, and stress responses through multiple pathways, including direct GABA production and vagus nerve signaling.
Source: Nature Reviews Neuroscience, 13(10), 701–712. doi.org/10.1038/nrn3346
Dinan, T.G., Stanton, C. & Cryan, J.F. (2013): Psychobiotics — A Novel Class of Psychotropic
Coined the term “psychobiotics” for probiotic bacteria that produce mental health benefits. Argues that specific bacterial strains capable of producing GABA and other neurotransmitters represent a new class of interventions for mood and anxiety disorders.
Source: Biological Psychiatry, 74(10), 720–726. doi.org/10.1016/j.biopsych.2013.05.001
Strandwitz, P. (2018): Neurotransmitter Modulation by the Gut Microbiota
Reviews the mechanisms by which gut bacteria produce and modulate neurotransmitters including GABA, serotonin, and dopamine. Focuses on how microbial metabolites reach the brain and influence neural function.
Source: Brain Research, 1693, 128–133. doi.org/10.1016/j.brainres.2018.03.015
Wallace, C.J.K. & Milev, R. (2017): The Effects of Probiotics on Depressive Symptoms in Humans — A Systematic Review
Systematic review finding that probiotic supplementation showed a significant overall effect on depressive symptoms. Supports the idea that modulating gut flora — and with it, neurotransmitter production including GABA — can influence mental health.
Source: Annals of General Psychiatry, 16(1), 14. doi.org/10.1186/s12991-017-0138-2
GABA in Medicine
Addolorato, G. et al. (2007): Effectiveness and Safety of Baclofen for Maintenance of Alcohol Abstinence
Randomized, double-blind, placebo-controlled trial demonstrating that baclofen — a GABA-B receptor agonist — effectively maintains alcohol abstinence in patients with liver cirrhosis. One of the landmark studies establishing baclofen as a treatment option for alcohol dependence.
Source: The Lancet, 370(9603), 1915–1922. doi.org/10.1016/S0140-6736(07)61814-5
Backonja, M.M. et al. (1998): Gabapentin Monotherapy for Diabetic Peripheral Neuropathy
Pivotal trial showing that gabapentin — a GABA-derived medication — effectively reduces pain in diabetic neuropathy. Established gabapentin as a first-line neuropathic pain treatment and demonstrated the clinical utility of GABA-modulating drugs beyond seizure control.
Source: JAMA, 280(21), 1831–1836. pubmed.ncbi.nlm.nih.gov/9846777
Cloos, J.M. & Ferreira, V. (2022): Benzodiazepines (StatPearls)
Up-to-date clinical reference on benzodiazepines — their mechanism of action at the GABA-A receptor, therapeutic uses, adverse effects, and dependence potential. Covers the pharmacology that explains both the effectiveness and the risks of these widely prescribed GABA-enhancing drugs.
Source: StatPearls Publishing. ncbi.nlm.nih.gov/books/NBK470159
Lux, A.L. et al. (2002): Randomized Trial of Vigabatrin in Patients with Infantile Spasms
Clinical trial demonstrating the effectiveness of vigabatrin — which works by blocking GABA breakdown — for infantile spasms (West syndrome). Illustrates how preserving endogenous GABA can have powerful therapeutic effects, particularly in pediatric epilepsy.
Source: Neurology, 59(4), 648–653. pubmed.ncbi.nlm.nih.gov/12196676
Mease, P.J. et al. (2008): Pregabalin Monotherapy in Fibromyalgia
Phase III trial confirming pregabalin’s efficacy in fibromyalgia — a condition characterized by widespread pain, sleep disturbance, and fatigue. Pregabalin modulates GABA-related calcium channels, providing another example of GABA-system drugs addressing complex symptom clusters.
Source: The Journal of Rheumatology, 35(3), 502–514. pubmed.ncbi.nlm.nih.gov/18278830
Skibiski, J. & Abdijadid, S. (2021): Barbiturates (StatPearls)
Clinical overview of barbiturates — the predecessors of benzodiazepines that also work through the GABA system but with a far narrower margin of safety. Documents their decline in clinical use and remaining niche applications.
Source: StatPearls Publishing. ncbi.nlm.nih.gov/books/NBK539731
How to Naturally Boost GABA
El Idrissi, A. (2008): Taurine as a Modulator of GABAergic Neurotransmission
Demonstrates taurine’s ability to activate GABA receptors and modulate GABAergic signaling. Shows that taurine acts as a partial GABA agonist, supporting the rationale for taurine supplementation as a way to gently enhance GABA function.
Source: Neurochemical Research, 33(1), 152–159.
Braga, J.D., Thongngam, M. & Kumrungsee, T. (2024): Gamma-Aminobutyric Acid as a Potential Postbiotic Mediator in the Gut-Brain Axis
Recent review exploring GABA as a “postbiotic” — a beneficial substance produced by gut bacteria. Examines how microbially produced GABA in the gut may influence brain function via the vagus nerve and other gut-brain communication pathways.
Source: npj Science of Food, 8, 16. nature.com/articles/s41538-024-00253-2
Streeter, C.C. et al. (2007): Yoga Asana Sessions Increase Brain GABA Levels — A Pilot Study
First study to demonstrate that yoga practice directly increases GABA levels in the human brain, as measured by magnetic resonance spectroscopy. Found a 27% increase in thalamic GABA after a single 60-minute yoga session compared to a reading control.
Source: Journal of Alternative and Complementary Medicine, 13(4), 419–426. pubmed.ncbi.nlm.nih.gov/17532734
Guglietti, C.L. et al. (2013): Meditation-Related Increases in GABA(B)-Modulated Cortical Inhibition
Used transcranial magnetic stimulation to show that experienced meditators have increased GABA-B mediated cortical inhibition. Provides a neurophysiological explanation for why meditation reduces anxiety and promotes calm.
Source: Brain Stimulation, 6(3), 397–402. doi.org/10.1016/j.brs.2012.07.002
Lancel, M. & Kovar, K.A. (1999): GABAergic Modulation of Sleep
Reviews the central role of GABA in sleep regulation. Explains how GABA-A receptor activation promotes sleep onset and maintenance, and why most prescription sleep aids work through the GABA system.
Source: Sleep Medicine Reviews, 3(1), 39–47.
Zhao, D. et al. (2018): Resveratrol Alleviates Anxiety-Like Behavior via Modulating GABAergic and Glutamatergic Systems
Animal study showing that resveratrol — found in red grapes — reduces anxiety by modulating the GABA-glutamate balance. Demonstrates how dietary compounds can influence brain chemistry through GABA-related pathways.
Source: Neurochemical Research, 43(12), 2241–2252.
GABA as a Dietary Supplement
Almutairi, S., Sivadas, A. & Kwakowsky, A. (2024): The Effect of Oral GABA on the Nervous System — Potential for Therapeutic Intervention
Recent comprehensive review of oral GABA supplementation studies. Evaluates the evidence for effects on stress, sleep, and relaxation, and discusses the ongoing debate about whether oral GABA crosses the blood-brain barrier or acts through peripheral mechanisms.
Source: Nutraceuticals, 4(2), 241–259. doi.org/10.3390/nutraceuticals4020015
Hinton, T. et al. (2019): Effect of GABA-Fortified Oolong Tea on Reducing Stress in a University Student Cohort
Controlled study showing that GABA-enriched tea significantly reduced stress markers in university students during exam periods. Suggests that even relatively modest amounts of dietary GABA can produce measurable calming effects.
Source: Frontiers in Nutrition, 6, 27. doi.org/10.3389/fnut.2019.00027
Abdou, A.M. et al. (2006): Relaxation and Immunity Enhancement Effects of GABA Administration in Humans
Demonstrated that oral GABA supplementation reduced anxiety and enhanced immune function under stress conditions. One of the earlier human studies providing evidence that supplemental GABA produces measurable physiological effects.
Source: BioFactors, 26(3), 201–208. doi.org/10.1002/biof.5520260305
Yoto, A. et al. (2012): Oral Intake of GABA Affects Mood and Activities of Central Nervous System During Stressed Condition
Showed that oral GABA intake reduced psychological stress markers and altered brain wave patterns during a stressful mental task. EEG measurements revealed changes consistent with a calming effect on the central nervous system.
Source: Amino Acids, 43(3), 1331–1337. doi.org/10.1007/s00726-011-1206-6
Boonstra, E. et al. (2015): Neurotransmitters as Food Supplements — The Effects of GABA on Brain and Behavior
Critical review examining the paradox of oral GABA: the evidence for calming effects is growing, yet the classical view holds that GABA cannot cross the blood-brain barrier. Discusses possible peripheral mechanisms and the need for more rigorous human trials.
Source: Frontiers in Psychology, 6, 1520. doi.org/10.3389/fpsyg.2015.01520
The Blood-Brain Barrier Myth
Roberts, E. & Frankel, S. (1950): γ-Aminobutyric Acid in Brain — Its Formation from Glutamic Acid
The paper that discovered GABA in the mammalian brain. Roberts and Frankel identified GABA as a product of glutamic acid decarboxylation — a finding that launched decades of neuroscience research into inhibitory neurotransmission.
Source: Journal of Biological Chemistry, 187(1), 55–63. pubmed.ncbi.nlm.nih.gov/15421926
Takanaga, H. et al. (2001): GAT2/BGT-1 as a System Responsible for the Transport of GABA at the Mouse Blood-Brain Barrier
Identified specific GABA transporter proteins at the blood-brain barrier, demonstrating that the barrier is not impermeable to GABA but contains active transport systems. Challenges the simplistic view that supplemental GABA cannot reach the brain.
Source: Journal of Cerebral Blood Flow & Metabolism, 21(10), 1232–1239.
Banks, W.A. et al. (2024): The Penetration of Therapeutics Across the Blood-Brain Barrier — Classic Case Studies and Clinical Implications
Recent review of how various substances cross the blood-brain barrier, including new evidence on transport mechanisms and barrier permeability variations. Contextualizes the GABA transport question within the broader field of CNS drug delivery.
Source: Cell Reports Medicine, 5(11), 101760. doi.org/10.1016/j.xcrm.2024.101760
GABA and the Vagus Nerve / What Do Doctors Know?
Herman, M.A. et al. (2009): GABA Signaling in the Nucleus Tractus Solitarius Sets the Level of Activity in the Vagovagal Circuit
Demonstrates how GABA signaling in the brainstem directly regulates vagus nerve activity. Provides the neuroanatomical basis for how GABA in the gut — even if it doesn’t cross the blood-brain barrier — could influence the brain through vagal pathways.
Source: American Journal of Physiology — GI and Liver Physiology, 296(1), G101–G111. doi.org/10.1152/ajpgi.90504.2008
Nakamura, U. et al. (2022): Dietary GABA Induces Satiation by Enhancing the Postprandial Activation of Vagal Afferent Nerves
Showed that dietary GABA activates vagal nerve fibers after meals, promoting satiety. Provides evidence for a peripheral mechanism of action for supplemental GABA — one that does not require crossing the blood-brain barrier.
Source: Nutrients, 14(12), 2492. doi.org/10.3390/nu14122492
Anxiety and Panic Disorders
Stein, M.B. & Sareen, J. (2015): Generalized Anxiety Disorder
Authoritative New England Journal of Medicine review of generalized anxiety disorder. Covers the role of GABA system dysfunction in the pathophysiology of anxiety, current treatment approaches, and the biological basis of why benzodiazepines (GABA-A agonists) are effective but problematic long-term.
Source: NEJM, 373(21), 2059–2068. doi.org/10.1056/NEJMcp1502514
Sartori, S.B. & Singewald, N. (2019): Novel Pharmacological Targets for the Treatment of Anxiety
Reviews emerging drug targets for anxiety beyond traditional benzodiazepines, including GABA-A receptor subtype-selective compounds. Maps the future of GABA-based anxiety treatment toward more precise, less addictive interventions.
Source: Pharmacology & Therapeutics, 204, 107402. doi.org/10.1016/j.pharmthera.2019.107402
Lydiard, R.B. (2003): The Role of GABA in Anxiety Disorders
Foundational clinical review of GABA’s involvement in anxiety disorders, covering both the biological evidence for GABA deficits in anxiety patients and the clinical response to GABA-enhancing medications.
Source: Journal of Clinical Psychiatry, 64(Suppl 3), 21–27. pubmed.ncbi.nlm.nih.gov/12662130
Relaxation and Sleep
Almutairi, S. et al. (2020): Effects of Oral GABA Administration on Stress and Sleep in Humans — A Systematic Review
The most comprehensive systematic review of oral GABA supplementation studies to date. Found evidence that GABA reduces stress markers and improves sleep quality, though noted that dosages varied considerably across studies, complicating direct comparisons.
Source: Frontiers in Neuroscience, 14, 923. doi.org/10.3389/fnins.2020.00923
Winkelman, J.W. et al. (2008): Reduced Brain GABA in Primary Insomnia
Used proton magnetic resonance spectroscopy to demonstrate that insomnia patients have approximately 30% less GABA in their brains compared to good sleepers. Established a direct link between GABA levels and sleep ability.
Source: Sleep, 31(11), 1499–1506.
Yoto, A. et al. (2019): GABA and L-Theanine Mixture Decreases Sleep Latency and Improves NREM Sleep
Found that combining GABA with L-theanine reduced the time to fall asleep and improved non-REM sleep quality more effectively than either substance alone. Supports the “sleep cocktail” approach of combining complementary GABA-supporting substances.
Source: Journal of Clinical Biochemistry and Nutrition, 64(1), 1–5. pubmed.ncbi.nlm.nih.gov/30707852
Allen, R.P. et al. (2014): Restless Legs Syndrome and Central Nervous System GABA
Found reduced GABA-related activity in the brains of restless legs syndrome patients, suggesting that GABA dysfunction may contribute to this sleep-disrupting condition. Supports the use of GABA-modulating treatments for RLS.
Source: Sleep Medicine, 15(7), 761–765. pubmed.ncbi.nlm.nih.gov/25129262
Burnout
Gold, P.W. (2015): The Organization of the Stress System and Its Dysregulation in Depressive Illness
Describes how chronic stress dysregulates the body’s stress response system, leading to depression and burnout. Covers the downstream effects on neurotransmitter systems including GABA, providing the biochemical framework for understanding burnout as a neurochemical disorder.
Source: Molecular Psychiatry, 20(1), 32–47. doi.org/10.1038/mp.2014.163
Holmes, S.E. et al. (2019): Lower Synaptic Density Is Associated with Depression Severity
Used PET imaging to show that synaptic density is reduced in depressed patients — and the reduction correlates with symptom severity. Demonstrates the physical brain changes underlying depression and burnout at the cellular level.
Source: Nature Communications, 10(1), 1529. doi.org/10.1038/s41467-019-09562-7
Boyle, N.B., Lawton, C. & Dye, L. (2017): The Effects of Magnesium Supplementation on Subjective Anxiety and Stress — A Systematic Review
Systematic review finding that magnesium supplementation can reduce subjective measures of anxiety and stress. Relevant because magnesium supports GABA receptor function, suggesting a simple dietary intervention for stress-related symptoms.
Source: Nutrients, 9(5), 429. doi.org/10.3390/nu9050429
Kimura, K. et al. (2007): L-Theanine Reduces Psychological and Physiological Stress Responses
Demonstrated that L-theanine — the calming amino acid from green tea — reduces both psychological stress measures and physiological markers like heart rate during a stressful mental task. Supports L-theanine as a gentle, non-sedating GABA supporter.
Source: Biological Psychology, 74(1), 39–45. doi.org/10.1016/j.biopsycho.2006.06.006
ADHD
Edden, R.A.E. et al. (2012): Reduced GABA Concentration in Attention-Deficit/Hyperactivity Disorder
First study to directly measure reduced GABA concentrations in the brains of children with ADHD using magnetic resonance spectroscopy. Provides hard neurochemical evidence for GABA’s involvement in attention and impulse control deficits.
Source: Archives of General Psychiatry, 69(7), 750–753. pmc.ncbi.nlm.nih.gov/articles/PMC3970207
Puts, N.A.J. et al. (2020): Reduced GABAergic Inhibition and Abnormal Sensory Processing in Children with ADHD
Found that children with ADHD show reduced GABA-mediated inhibition, which correlates with difficulties in sensory processing. Suggests that GABA deficits contribute to the sensory overwhelm many ADHD patients experience.
Source: NeuroImage: Clinical, 27, 102348. doi.org/10.1016/j.nicl.2020.102348
Hidese, S. et al. (2024): L-Theanine Supplementation Reduces Psychiatric Symptoms in ADHD
Recent study showing that L-theanine supplementation — which supports GABA function — can reduce psychiatric symptoms in ADHD patients. Suggests a role for GABA-supporting supplements as an adjunct to standard ADHD treatment.
Source: BMC Psychiatry, 24, 6285. doi.org/10.1186/s12888-024-06285-y
Mousain-Bosc, M. et al. (2006): Magnesium and Vitamin B6 Improve Symptoms in Children with ADHD
Found that combined magnesium and vitamin B6 supplementation improved ADHD symptoms in children. Both nutrients support GABA synthesis and function, providing a mechanistic rationale for the clinical improvement.
Source: Magnesium Research, 19(4), 267–273. ncbi.nlm.nih.gov/pmc/articles/PMC4757677
OCD (Obsessive-Compulsive Disorder)
Hepsomali, P. et al. (2020): Effects of Oral GABA Administration on Stress and Sleep in Humans
Systematic review relevant to OCD because it demonstrates that oral GABA can modulate stress responses — and chronic stress is a major trigger for OCD symptom flare-ups. The calming effects documented here may help explain anecdotal reports of GABA supplementation easing OCD-related anxiety.
Source: Frontiers in Neuroscience, 14, 923. doi.org/10.3389/fnins.2020.00923
⚠️ Note: Several OCD sources in the German bibliography are German-language only (dissertations, German news outlets). They have been omitted from this English-language list. The core scientific claim — that GABA-glutamate imbalance plays a role in OCD — is covered by the Hepsomali review and standard neuroscience textbooks listed above.
Emotional Eating, Stress Eating, and Binge-Eating
Guardia, D. et al. (2011): GABAergic and Glutamatergic Modulation in Binge Eating — Therapeutic Approach
Reviews the evidence that GABA-glutamate imbalance contributes to binge-eating episodes. Discusses how baclofen (a GABA-B agonist) reduces binge-eating urges, and how GABA’s role in impulse control connects to disordered eating behaviors.
Source: Current Pharmaceutical Design, 17(14), 1396–1409. doi.org/10.2174/138161211796150828
Hasler, G. et al. (2010): Effect of Acute Psychological Stress on Prefrontal GABA Concentration
Used MRS imaging to show that acute stress measurably drops GABA levels in the prefrontal cortex — the brain region responsible for impulse control. Directly relevant to understanding why stress triggers impulsive eating behaviors.
Source: American Journal of Psychiatry, 167(10), 1226–1231. doi.org/10.1176/appi.ajp.2010.09070994
Addiction and Withdrawal
Volkow, N.D., Koob, G.F. & McLellan, A.T. (2016): Neurobiologic Advances from the Brain Disease Model of Addiction
Authoritative NEJM review establishing addiction as a chronic brain disorder with identifiable neurobiological mechanisms. Covers the role of GABA system disruption in addiction, tolerance, and withdrawal across substance classes.
Source: NEJM, 374(4), 363–371. doi.org/10.1056/NEJMra1511480
Malcolm, R.J. (2003): GABA Systems, Benzodiazepines, and Substance Dependence
Reviews the central role of the GABA system in substance dependence — particularly for alcohol, benzodiazepines, and barbiturates. Explains why cross-tolerance occurs between these substances and why withdrawal from any of them threatens the same GABA-glutamate balance.
Source: Journal of Clinical Psychiatry, 64(Suppl 3), 36–40.
Alcohol
Addolorato, G. et al. (2000): Ability of Baclofen in Reducing Alcohol Craving and Intake
Preliminary clinical evidence that the GABA-B agonist baclofen reduces both alcohol craving and consumption. An early study that paved the way for baclofen’s adoption as an off-label treatment for alcohol dependence.
Source: Alcoholism: Clinical and Experimental Research, 24(1), 67–71. doi.org/10.1111/j.1530-0277.2000.tb00613.x
Addolorato, G. et al. (2012): Novel Therapeutic Strategies for Alcohol and Drug Addiction — Focus on GABA
Reviews emerging GABA-based therapeutic strategies for addiction, including GABA-B receptor agonists, ion channel modulators, and transcranial magnetic stimulation. Argues for a shift toward GABA-targeted treatments in addiction medicine.
Source: Neuropsychopharmacology, 37(1), 163–177. doi.org/10.1038/npp.2011.216
Benzodiazepines
Rickels, K. et al. (1990): Long-Term Therapeutic Use of Benzodiazepines — Effects of Abrupt Discontinuation
Landmark study documenting the withdrawal syndrome that occurs when long-term benzodiazepine users abruptly stop. Demonstrates the severity of GABA-system rebound effects and the importance of gradual tapering under medical supervision.
Source: Archives of General Psychiatry, 47(10), 899–907. doi.org/10.1001/archpsyc.1990.01810100063009
Heberlein, A. et al. (2009): Benzodiazepine Dependence — Causalities and Treatment Options
Reviews the mechanisms of benzodiazepine dependence — specifically how chronic use downregulates GABA-A receptors, creating the paradox where the medication eventually worsens the anxiety it was prescribed to treat.
Source: Fortschritte der Neurologie · Psychiatrie, 77(1), 7–15. doi.org/10.1055/s-0028-1100831
Pain Medications (Opioids)
Kosten, T.R. & O’Connor, P.G. (2003): Management of Drug and Alcohol Withdrawal
NEJM clinical review covering the management of withdrawal from multiple substance classes, including the role of GABA-modulating medications (benzodiazepines, gabapentin) in easing withdrawal symptoms. Standard reference for understanding the GABA system’s involvement in withdrawal management.
Source: NEJM, 348(18), 1786–1795. doi.org/10.1056/NEJMra020617
Roberto, M. et al. (2004): Increased GABA Release During Morphine Withdrawal
Demonstrates that opioid withdrawal increases GABA release in the amygdala — part of the brain’s stress circuit. This paradoxical increase in GABA release may represent a compensatory response to the overall excitatory state of withdrawal.
Source: Journal of Neuroscience, 24(13), 3339–3344. doi.org/10.1523/JNEUROSCI.0490-04.2004
Cocaine, Methamphetamine: GABA and Stimulant Withdrawal
Johnson, B.A. et al. (2013): Topiramate for the Treatment of Cocaine Addiction
Randomized clinical trial demonstrating that topiramate — which enhances GABA-A activity and blocks glutamate — reduces cocaine use in dependent individuals. One of the most robust trials supporting GABA-based pharmacotherapy for stimulant addiction.
Source: JAMA Psychiatry, 70(12), 1338–1346. doi.org/10.1001/jamapsychiatry.2013.2295
Jiao, D. et al. (2015): The Role of the GABA System in Amphetamine-Type Stimulant Use Disorders
Reviews how amphetamine-type stimulants disrupt the GABA system and how this disruption contributes to addiction, tolerance, and the difficulty of withdrawal. Discusses GABA-modulating drugs as potential treatment tools.
Source: Frontiers in Cellular Neuroscience, 9, 162. doi.org/10.3389/fncel.2015.00162
Note: No controlled studies exist for plain GABA supplementation in stimulant withdrawal. The studies listed here involve GABA-modulating medications (gabapentin, baclofen, topiramate).
Cannabis
Castillo, P.E. et al. (2012): Endocannabinoid Signaling and Synaptic Function
Comprehensive review of how the endocannabinoid system regulates synaptic transmission — including its tight interaction with GABAergic signaling. Explains why cannabis use can disrupt the GABA-glutamate balance and lead to anxiety and sleep problems upon cessation.
Source: Neuron, 76(1), 70–81. doi.org/10.1016/j.neuron.2012.08.011
Levin, F.R. et al. (2012): Gabapentin for Cannabis Dependence — A Proof-of-Concept Pilot Study
Pilot study suggesting that gabapentin — a GABA-derived medication — may reduce cannabis use and withdrawal symptoms. Provides preliminary evidence that restoring GABA function can help with cannabis cessation.
Source: Journal of Clinical Psychopharmacology, 32(3), 283–286. doi.org/10.1097/JCP.0b013e31824d612e
GABA in Sports
Powers, M.E. et al. (2008): Growth Hormone Isoform Responses to GABA Ingestion at Rest and After Exercise
Found that oral GABA supplementation increased growth hormone levels both at rest and after resistance exercise. A key study for the sports chapter, as growth hormone is critical for muscle recovery, fat metabolism, and tissue repair.
Source: Medicine & Science in Sports & Exercise, 40(1), 104–110. pubmed.ncbi.nlm.nih.gov/18091016
Devries, M.C. et al. (2008): Oral Supplementation Using GABA and Whey Protein Improves Whole Body Fat-Free Mass in Men After Resistance Training
Demonstrated that combining GABA with whey protein produced greater increases in lean body mass after resistance training compared to whey protein alone. Supports the use of GABA supplementation in athletic recovery protocols.
Source: Journal of Strength and Conditioning Research, 22(5), 1610–1617.
Matsumoto, K. et al. (2022): Effect of Oral Administration of GABA on Thermoregulation in Athletes During Exercise in Cold Environments
Preliminary study showing GABA’s influence on thermoregulation during cold-weather exercise. Suggests that GABA’s calming effects extend to autonomic nervous system regulation during athletic performance.
Source: Frontiers in Nutrition, 9, 883571. frontiersin.org
GABA’s Strong Helpers — Substances That Calm the Nervous System Together
Jia, F. et al. (2008): Taurine Is a Potent Activator of Extrasynaptic GABA-A Receptors in the Thalamus
Showed that taurine potently activates a specific type of GABA-A receptor outside the synapse — “extrasynaptic” receptors responsible for tonic inhibition. This mechanism explains taurine’s gentle but sustained calming effect, distinct from drugs that target synaptic receptors.
Source: Journal of Neuroscience, 28(25), 6581–6589. doi.org/10.1523/JNEUROSCI.0469-08.2008
Schaffer, S. & Kim, H.W. (2018): Effects and Mechanisms of Taurine as a Therapeutic Agent
Comprehensive review of taurine’s neuroprotective properties, including its role as a GABA-A receptor modulator, antioxidant, and anti-inflammatory agent. Covers the evidence for taurine supplementation in neurological and psychiatric conditions.
Source: Biomolecules & Therapeutics, 26(3), 225–241. doi.org/10.4062/biomolther.2017.251
Dashwood, R. & Visioli, F. (2025): L-Theanine — From Tea Leaf to Trending Supplement
Recent critical review examining whether the scientific evidence for L-theanine’s brain health and relaxation benefits matches the marketing hype. Concludes that while evidence for calming effects is solid, claims about cognitive enhancement need more robust trials.
Source: Nutrition Research, 134, 39–48. doi.org/10.1016/j.nutres.2024.12.008
Al Alawi, A.M. et al. (2018): Magnesium and Human Health — Perspectives and Research Directions
Reviews magnesium’s role across multiple body systems, with particular attention to its effects on the nervous system. Covers the evidence linking magnesium deficiency to anxiety, sleep problems, and GABA dysfunction.
Source: International Journal of Endocrinology, 2018, 9041694. doi.org/10.1155/2018/9041694
Dhawan, K. et al. (2004): Passiflora — A Review Update
Comprehensive review of passionflower’s pharmacology, including its mechanisms for enhancing GABA activity. Covers the evidence for its traditional use as a natural sedative and anxiolytic and the modern research confirming these effects.
Source: Journal of Ethnopharmacology, 94(1), 1–23. doi.org/10.1016/j.jep.2004.07.009
Frederickson, C.J. et al. (2005): The Neurobiology of Zinc in Health and Disease
Reviews zinc’s role as a neuromodulator, including its influence on GABA-A receptors. Zinc modulates how strongly GABA can activate its receptors, making it a crucial mineral for optimal GABA function.
Source: Nature Reviews Neuroscience, 6(6), 449–462. doi.org/10.1038/nrn1671
Gasperi, V. et al. (2019): Niacin in the Central Nervous System — An Update of Biological Aspects and Clinical Applications
Reviews niacin’s (vitamin B3) multiple roles in the brain, including its influence on GABA receptor function. Niacinamide, in particular, can bind to GABA-A receptors and enhance their activity — making it a “quiet supporter” of the GABA system.
Source: International Journal of Molecular Sciences, 20(4), 974. doi.org/10.3390/ijms20040974
Levine, J. et al. (1997): Controlled Trials of Inositol in Psychiatry
Meta-analysis of eight double-blind studies showing inositol’s efficacy in panic disorder and depression. Inositol modulates intracellular signaling downstream of GABA receptors, offering a subtle but meaningful support to the GABAergic system.
Source: Human Psychopharmacology, 12(4), 293–304.
Ciranna, L. (2006): Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission
Explains the bidirectional relationship between serotonin and the GABA-glutamate system. Shows that serotonin can either enhance or inhibit GABAergic transmission depending on the receptor subtype involved — foundational for understanding the GABA-serotonin alliance.
Source: Neuropharmacology, 51(2–3), 101–114. doi.org/10.1016/j.neuropharm.2006.02.011
This bibliography is maintained by Guzek Verlagsgesellschaft mbH, Vienna.
Last updated: July 2026